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Abstract
Background: People with central obesity have an increased risk for developing the metabolic syndrome, type 2
diabetes and cardiovascular disease. However, a substantial part of obese individuals have no other cardiovascular
risk factors, besides their obesity. High sensitivity C-reactive protein (hs-CRP), a marker of systemic inflammation
and a predictor of type 2 diabetes and cardiovascular disease, is associated with the metabolic syndrome and its
separate components. We evaluated the use of hs-CRP to discriminate between centrally obese people with and
without the metabolic syndrome.
Methods: 1165 people with central obesity but without any previous diagnosis of hypertension, dyslipidemia,
diabetes or cardiovascular disease, aged 20-70 years, underwent a physical examination and laboratory assays to
determine the presence of the metabolic syndrome (NCEP ATP III criteria). Multivariable linear regression analyses
were performed to assess which metabolic syndrome components were independently associated with hs-CRP. A
ROC curve was drawn and the area under the curve was calculated to evaluate whether hs-CRP was capable to
predict the presence of the metabolic syndrome.
Results: Median hs-CRP levels were significantly higher in individuals with central obesity with the metabolic
syndrome (n = 417; 35.8%) compared to individuals with central obesity without the metabolic syndrome (2.2 mg/
L (IQR 1.2-4.0) versus 1.7 mg/L (IQR 1.0-3.4); p < 0.001). Median hs-CRP levels increased with an increasing number
of metabolic syndrome components present. In multivariable linear regression analyses, waist circumference and
triglycerides were the only components that were independently associated with hs-CRP after adjusting for
smoking, gender, alcohol consumption and the other metabolic syndrome components. The area under the ROC
curve was 0.57 (95%-CI 0.53-0.60).
Conclusions: Hs-CRP has limited capacity to predict the presence of the metabolic syndrome in a population with
central obesity.
Keywords: Abdominal obesity, Metabolic syndrome, Screening, High-sensitivity C-reactive protein
Background
The metabolic syndrome (MetS) is a cluster of cardiovas-
cular risk factors associated with an increased risk for
developing cardiovascular disease and type 2 diabetes [1].
In recent years systemic inflammation - which can be
measured by high sensitivity C-reactive protein (hs-CRP)
- has become an important marker for cardiovascular dis-
ease and type 2 diabetes [2-4]. Moreover hs-CRP is asso-
ciated with the MetS and its separate components. Early
diagnosis of the MetS is desirable as lifestyle interven-
tions and adequate treatment of risk factors associated
with the MetS can prevent cardiovascular disease [5,6].
However, it is not clear whether hs-CRP can also predict
the presence of the MetS. Previous research showed that
measuring an increased waist circumference was a reli-
able first step in detecting individuals with the MetS and
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the individuals with central obesity have no other cardio-
vascular risk factors [8,9]. Further assessment of risk for
cardiovascular disease, after initial (self-)measurement of
waist circumference, involves physical examination and
laboratory assays. An elevated hs-CRP could be used to
further distinguish those with the MetS from those with-
out and diminish the group qualifying for further exami-
nations. Therefore the aim of this study was to evaluate
the use of hs-CRP to discriminate those with the MetS
from those without the MetS in a population with central
obesity.
Methods
Study design and participants
A cross-sectional screening study was performed in five
primary health care centres in IJsselstein, a small city in
the centre of the Netherlands. The aim was to determine
the feasibility of screeningf o rt h eM e t Sb ym e a s u r i n g
waist circumference as a first step and to assess the pre-
valence of the MetS [7]. Almost 12000 individuals
received a tape measure to determine their own waist cir-
cumference. They were 20 to 70 years old and had no
previous diagnosis of cardiovascular disease, diabetes,
hypertension or dyslipidemia, nor did they use medica-
tion for any of these conditions. Individuals with an
increased self-measured waist circumference (≥ 88 cm in
women; ≥ 102 cm in men) were invited for further exam-
inations. Between September 2006 and May 2007, 1721
individuals with an increased self-measured waist cir-
cumference underwent all study procedures. Only parti-
cipants with actual central obesity (a waist circumference
≥ 88 cm in women and ≥ 102 cm in men, measured by
the investigators) were included in the present analyses.
The study was approved by the medical ethics com-
mittee of the University Medical Center Utrecht, the
Netherlands. Written informed consent was obtained
from all participants.
Measurements
In a physical examination body weight, height, waist cir-
cumference and blood pressure were measured. Examina-
tions were described in detail previously [7]. Venous blood
samples were drawn after an overnight fast to determine
fasting blood glucose, lipids (triglycerides, total cholesterol,
LDL cholesterol and HDL cholesterol) and hs-CRP. LDL
cholesterol was calculated using the Friedewald formula.
Hs-CRP was analysed by latex-enhanced turbidimetric
assay (Cobas Integra 800 Analyzer, Roche Diagnostics).
The participants completed a questionnaire to deter-
mine ethnicity, lifestyle factors (smoking habits, alcohol
use, and physical activity), relevant medical history, socio-
economic and demographic variables. Physical activity was
assessed using the validated SQUASH questionnaire [10],
which measures habitual activities with respect to occupa-
tion, leisure time, household tasks, transportation means,
and other daily activities. The results were dichotomised
based on the Dutch Standard Healthy Movement: a mini-
mum of thirty minutes of exercise at least five days a week
[11]. The use of alcohol was divided into three categories:
no alcohol consumption, moderate alcohol consumption
(one to 14 units per week for women, one to 21 units per
week for men) and excessive alcohol consumption (more
than 14 units per week for women, more than 21 units per
week for men). Smoking was regarded positive when the
participant was currently smoking tobacco; in case of for-
mer or never smoking it was regarded negative.
Participants were informed about the results of physi-
cal and laboratory examinations and in case of detected
cardiovascular risk factors they received usual care by
their general practitioner [12].
Outcome measure
T h ep r e s e n c eo ft h eM e t Sw a sd e f i n e db yt h ec r i t e r i ao f
the NCEP ATP III [13]. The diagnosis was made when at
least three of the five following criteria were present:
waist circumference ≥ 88 cm (women) or ≥ 102 cm
(men); triglycerides ≥ 1.7 mmol/L; HDL cholesterol < 1.3
mmol/L (women) or < 1.0 mmol/L (men); blood pressure
≥ 130/≥ 85 mmHg; fasting glucose ≥ 6.1 mmol/L.
Data analyses
All statistical analyses were performed with SPSS, version
15.0 (SPSS, Chigaco, Illinois). Categorical variables are
reported as numbers and percentages, continuous variables
as means with standard deviations (SD) and non normally
distributed variables as median with interquartile range
(IQR). Differences between groups were analysed with Chi-
square tests for categorical variables, independent t-tests
for normally distributed continuous variables and Mann-
Whitney tests for non normally distributed continuous
variables. Hs-CRP was divided into three categories based
on the cut-off points for risk stratification for cardiovascu-
lar risk [14]. A level below 1.0 mg/L is considered a low
cardiovascular risk, between 1.0 and 3.0 mg/L an inter-
mediate risk and between 3.0 and 10.0 mg/L a high risk. A
level above 10.0 mg/L is associated with active infection
and therefore not applicable in the risk estimation [15].
Individuals with an hs-CRP level above 10.0 mg/L were
excluded from the analyses.
Univariable linear regression analyses were used to cal-
culate the p for trend over hs-CRP categories, in which
the hs-CRP categories were used as independent variable.
A multivariable linear regression analysis was performed
to assess which MetS components were independently
associated with hs-CRP. In this analysis hs-CRP and tri-
glycerides were logtransformed because of their skewed
distribution. Waist circumference and HDL cholesterol
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specific thresholds. The gender specific threshold was
extracted from the values obtained in the examinations.
The new variables indicate the absolute difference with
the gender specific threshold. A ROC curve was drawn
and the area under the curve was calculated to evaluate
whether hs-CRP is capable to predict the presence of the
MetS. Sensitivity, specificity and the positive and negative
predictive values for different hs-CRP cut-off points were
calculated.
Results
Of the 1721 participants with a self-measured increased
waist-circumference that completed all study procedures
108 individuals were excluded from the analyses because
of an hs-CRP above 10.0 mg/L. 1165 individuals had an
actual increased waist circumference, measured by the
investigator. The mean age in the participants with an
actual increased waist circumference was 48.4 (SD 10.7)
years, 92.7% were Caucasian and 65.2% were female. The
prevalence of MetS in this population with central obe-
sity was 35.8% (n = 417). Table 1 shows the patient char-
acteristics for the individuals with an increased waist
circumference with and without the MetS. The median
hs-CRP for the total population was 1.9 mg/L (IQR 1.1-
3.6). In the population with the MetS the median hs-CRP
was 2.2 mg/L (IQR 1.2-4.0), compared to 1.7 mg/L (IQR
1.0-3.4) in the group without the MetS (p < 0.001).
With an increasing number of MetS components
present, median hs-CRP increased from 1.5 mg/L (IQR
0.9-2.9) to 1.9 (IQR 1.1-3.5), 2.1 (IQR 1.1-4.0), 2.4 (IQR
1.5-4.5) and 2.2 mg/L (IQR 1.4-4.4) in the groups with
respectively one (n = 234), two (n = 514), three (n =
301), four (n = 103) and five (n = 13) components
(p for trend < 0.001).
Table 2 shows the clinical and biochemical character-
istics according to hs-CRP categories. A significant lin-
ear trend over increasing hs-CRP categories was seen
for the presence of the MetS and for three of its compo-
nents: waist circumference, triglycerides and HDL cho-
lesterol. BMI, gender, current tobacco smoking and
current alcohol consumption also showed a significant
linear trend. In a multivariable linear regression analysis,
waist circumference and triglycerides were the only
MetS components that were independently associated
with hs-CRP, after adjusting for smoking, gender, alco-
hol consumption and the other MetS components
(Table 3).
T h ea r e au n d e rt h eR O Cc u r v ef o rh s - C R Pw a s0 . 5 7
(95%-CI 0.53-0.60) (Figure 1).
Table 1 Patient characteristics for the total population and according to the presence of the metabolic syndrome
Characteristics Total n = 1165 Metabolic syndrome present n = 417 Metabolic syndrome absent n = 748 P-value
Age (years) 48.4 ± 10.7 48.5 ± 10.5 48.3 ± 10.8 0.76
Gender (%, female) 65.2 48.0 74.9 < 0.001
Waist circumference (cm)
- Female 97.7 ± 8.1 100.3 ± 9.2 96.7 ± 7.4 < 0.001
- Male 109.7 ± 6.6 110.5 ± 6.9 108.9 ± 6.3 0.01
BMI (kg/m
2) 29.5 ± 3.6 30.3 ± 3.6 29.1 ± 3.5 < 0.001
Blood pressure (mmHg)
- Systolic 137.7 ± 17.3 144.8 ± 15.8 133.7 ± 16.8 < 0.001
- Diastolic 84.8 ± 9.3 88.7 ± 7.9 82.7 ± 9.3 < 0.001
Triglycerides (mmol/L) 1.2 (0.9-1.8) 1.9 (1.7-2.4) 1.0 (0.8-1.3) < 0.001
HDL cholesterol (mmol/L)
- Female 1.6 ± 0.4 1.3 ± 0.3 1.7 ± 0.4 < 0.001
- Male 1.2 ± 0.3 1.1 ± 0.3 1.4 ± 0.2 < 0.001
LDL cholesterol (mmol/L) 3.2 ± 0.9 3.4 ± 0.9 3.2 ± 0.8 < 0.001
Fasting glucose (mmol/L) 5.0 ± 0.9 5.4 ± 1.4 4.9 ± 0.5 < 0.001
Hs-CRP (mg/L) 1.9 (1.1-3.6) 2.2 (1.2-4.0) 1.7 (1.0-3.4) < 0.001
Physical activity meeting Dutch 59.5 56.1 61.3 0.09
Standard Healthy Movement
‡ (%)
Current smoking (%) 20.3 24.6 17.9 0.01
Alcohol consumption (%) 0.03
- None 28.3 31.1 26.7
- Moderate 64.5 59.8 67.1
- Excessive 7.2 9.2 6.2
Data are reported as means ± standard deviation or percentage. Non normally distributed variables are reported as median (25th-75th percentile).
‡ Dutch Standard Healthy Movement: a minimum of thirty minutes of exercise at least five days a week.
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sensitivity and specificity of hs-CRP for the MetS were 82%
and 24%, respectively. The positive and negative predictive
values for this level were 38% and 71% respectively. At a
cut-off level of 3.0 mg/L the sensitivity and specificity were
37% and 72% respectively. The positive and negative pre-
dictive values for this level were 42% and 67% respectively.
Discussion
Median hs-CRP levels were significantly higher in indivi-
duals with central obesity with the MetS compared to
Table 2 Patient characteristics across hs-CRP cardiovascular risk level categories
hs-CRP (mg/L) P for trend
< 1.0 n = 254 ≥ 1.0-≤ 3.0 n = 545 > 3.0-< 10.0 n = 366
Age (years) 47.9 ± 10.6 49.6 ± 10.6 47.0 ± 10.7 0.15
Gender (%, female) 61.0 61.5 73.8 < 0.001
Waist circumference (cm)
- Female 95.0 ± 5.5 96.8 ± 7.6 100.3 ± 9.0 < 0.001
- Male 106.9 ± 3.4 110.0 ± 6.2 112.1 ± 8.6 < 0.001
Triglycerides (mmol/L) 1.1 (0.8-1.6) 1.2 (0.9-1.8) 1.3 (0.9-1.8) < 0.01
LDL cholesterol (mmol/L) 3.2 ± 0.9 3.2 ± 0.8 3.2 ± 0.9 0.78
HDL cholesterol (mmol/L)
- Female 1.7 ± 0.4 1.6 ± 0.4 1.5 ± 0.4 < 0.001
- Male 1.3 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 0.02
Blood pressure (mmHg)
- Systolic 135.7 ± 15.4 138.2 ± 17.5 138.3 ± 18.1 0.09
- Diastolic 84.2 ± 8.5 84.8 ± 9.3 85.3 ± 9.8 0.12
Fasting glucose (mmol/L) 5.0 ± 0.7 5.0 ± 1.0 5.1 ± 1.0 0.10
BMI (kg/m
2) 28.3 ± 3.0 29.4 ± 3.2 30.6 ± 4.2 < 0.001
Metabolic syndrome (%) 29.5 34.7 41.8 < 0.01
Current smoking (%) 19.3 17.6 25.0 0.05
Drinking alcohol (%) < 0.01
- None 20.9 27.9 34.0
- Moderate 70.5 64.9 59.7
- Excessive 8.7 7.2 6.3
Physical activity meeting Dutch Standard Healthy Movement
‡ (%) 55.5 61.3 59.5 0.41
Data are reported as means ± standard deviation or percentage. Non normally distributed variables are reported as median (25th-75th percentile).
‡ Dutch Standard Healthy Movement: a minimum of thirty minutes of exercise at least five days a week.
Table 3 Associations between metabolic syndrome
components and hs-CRP in multivariable linear
regression analysis
B (95%-CI) P-value
Waist circumference (cm) 0.03 (0.02; 0.03) < 0.001
Triglycerides (mmol/L) 0.21 (0.10; 0.32) < 0.001
HDL cholesterol (mmol/L) -0.06 (-0.20; 0.09) 0.43
Systolic blood pressure (mmHg) 0.00 (-0.00; 0.01) 0.11
Fasting glucose (mmol/L) -0.02 (-0.08; 0.03) 0.37
B, unstandardized regression coefficient, adjusted for gender, smoking status,
alcohol consumption and the other metabolic syndrome components. CI,
confidence interval.
Figure 1 ROC curve showing that the capacity of hs-CRP to
detect the presence of the metabolic syndrome in a
population with central obesity is limited. The area under the
ROC curve is 0.57 (95%-CI 0.53-0.60).
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hs-CRP levels increased with an increasing number of
MetS components present. The presence of the MetS,
waist circumference, triglycerides and HDL cholesterol
showed a significant trend over increasing hs-CRP cate-
gories. However the area under the ROC curve was 0.57,
indicating that hs-CRP cannot predict the presence of the
MetS in a population with central obesity.
Strengths of this study were the large number of people
and the wide variety in age, also including younger people.
Our study population consisted of individuals without
known cardiovascular disease, diabetes, hypertension or
dyslipidemia; besides an increased waist circumference
they were considered healthy. However because of their
increased waist circumference they were at risk for devel-
oping cardiovascular disease and were therefore a relevant
population for studying the use of hs-CRP as a screening
tool for early detection of the MetS.
A limitation of this study was the cross-sectional design.
We only performed measurements at one time point. Hs-
CRP is a sensitive marker for acute phase inflammation
and has a high within-subject variability [16]. A value
above five might indicate an increased cardiovascular risk,
but could also be an hs-CRP returning to normal low
levels after an infection [14]. However, since we intended
to explore the predictive value of hs-CRP measured at one
time point for detecting the presence of the MetS, our
design reflects routine in daily practice.
We found hs-CRP levels to be higher in centrally obese
individuals with the MetS, compared to those without.
This is in line with several studies which found higher
hs-CRP levels in individuals with the MetS, both in obese
and non-obese populations and in Caucasian and non-
Caucasian populations [17-25]. Also a linear increase in
hs-CRP levels with an increasing number of components
of the MetS was described previously [18-21,23,25-27].
Over increasing hs-CRP risk level categories the percen-
tage of people with the MetS increased significantly. A
similar significant trend was found for mean waist cir-
cumference and HDL cholesterol and median triglyceride
levels. But only waist circumference and triglycerides
showed a significant independent association with hs-
CRP in multivariable analysis. Several studies have
assessed the relation between hs-CRP and different MetS
components. In univariable analyses most of them
showed significant associations for the individual MetS
components. Studies that also assessed multivariable
associations, thereby adjusting for other MetS compo-
nents, mostly report that central obesity was the major
determinant of elevated hs-CRP levels in individuals with
the MetS. The other MetS components do not, or only
marginally, increase hs-CRP level [17-20,26,28]. This
might explain why hs-CRP cannot be used to predict the
presence of the MetS in our study, indicated by an area
under the ROC curve of 0.57.
The relationship between central obesity and increased
levels of hs-CRP has been well studied. Adipose tissue is
known to secrete cytokines that stimulate the produc-
tion of hs-CRP in the liver, but adipose tissue itself may
also secrete hs-CRP and thereby raise hs-CRP levels
[29]. Genetic polymorphisms could partially explain the
inter-individual variability observed in the inflammatory
profile of obese patients and the inter-individual varia-
bility in metabolic perturbations associated with obesity
[30,31].
Although central obesity seems to be the major deter-
minant of elevated hs-CRP levels in the MetS, significant
independent associations between hs-CRP and other
components were found. As in our study, Aronson et al.
found an independent association between triglyceride
level and hs-CRP. In addition they found associations
between hs-CRP and glucose level and HDL cholesterol.
However, this only accounted for ~1% of the variability
in CRP levels [26].
Two other studies also found an independent associa-
tion between hs-CRP and fasting glucose [21,32]. We
did not find such an association, which might be due to
the limited number of individuals with a high glucose
level (≥ 6.1 mmol/L) in our study population (n = 66;
5.7%). General practitioners in the Netherlands are alert
in screening for diabetes as a result of which the num-
ber of patients with undiagnosed diabetes is limited [33].
Conclusions
In our population with central obesity, measurement of
hs-CRP cannot be used to further discriminate MetS sta-
tus. The degree of central obesity seemed to be the main
determinant of an increased hs-CRP level; the association
with other MetS components was not strong enough to
enable further discrimination. While hs-CRP does not dis-
tinguish metabolic syndrome well on its own, it may have
utility in conjunction with other tests, which requires
further testing. In addition, hs-CRP could still be used as a
prognostic marker of cardiovascular disease and diabetes.
This would enable physicians to determine which centrally
obese individuals should be encouraged most strongly to
adapt a healthier lifestyle.
Abbreviations
Hs-CRP: High-sensitivity C-reactive protein; MetS: Metabolic syndrome
Acknowledgements
The IJsselstein Study of Central Obesity to detect metabolic syndrome was
supported in part by a research grant from the Investigator Initiated Studies
Program of Merck Sharp & Dome Corp (MSD). MSD had no role in the study
design and conduct, the writing of the manuscript or the decision to submit
the paper for publication. The opinions expressed in this presentation are
those of the authors and do not necessarily represent those of MSD.
den Engelsen et al. Cardiovascular Diabetology 2012, 11:25
http://www.cardiab.com/content/11/1/25
Page 5 of 7Author details
1Julius Center for Health Sciences and Primary Care, University Medical
Center Utrecht, Utrecht, The Netherlands.
2Huisartsenzorg IJsselstein, Locatie’t
Steyn, IJsselstein, The Netherlands.
Authors’ contributions
CdE and PSK researched the data, performed the statistical analyses and
wrote the manuscript. KJG, MvdD, PLS and GER contributed to the
discussion. All authors were involved in the design of the study and read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 January 2012 Accepted: 14 March 2012
Published: 14 March 2012
References
1. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ,
Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW,
Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J,
Wannamethee SG: Can metabolic syndrome usefully predict
cardiovascular disease and diabetes? Outcome data from two
prospective studies. Lancet 2008, 371:1927-1935.
2. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O’Reilly DS,
Packard CJ, Sattar N: C-reactive protein is an independent predictor of
risk for the development of diabetes in the West of Scotland Coronary
Prevention Study. Diabetes 2002, 51:1596-1600.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other
markers of inflammation in the prediction of cardiovascular disease in
women. N Engl J Med 2000, 342:836-843.
4. Ross R: Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:
S419-S420.
5. Ilanne-Parikka P, Eriksson JG, Lindstrom J, Peltonen M, Aunola S,
Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, Valle TT, Lahtela J,
Uusitupa M, Tuomilehto J: Effect of lifestyle intervention on the
occurrence of metabolic syndrome and its components in the Finnish
Diabetes Prevention Study. Diabetes Care 2008, 31:805-807.
6. Wong ND, Pio JR, Franklin SS, L’Italien GJ, Kamath TV, Williams GR:
Preventing coronary events by optimal control of blood pressure and
lipids in patients with the metabolic syndrome. Am J Cardiol 2003,
91:1421-1426.
7. Van den Donk M, Bobbink IWG, Gorter KJ, Salomé PL, Rutten GEHM:
Identifying people with metabolic syndrome in primary care by
screening with a mailed tape measure. A survey of 14,000 people in the
Netherlands. Prev Med 2009, 48:345-350.
8. Pataky Z, Bobbioni-Harsch E, Golay A: Open questions about metabolically
normal obesity. Int J Obes (Lond) 2010, 34(Suppl 2):S18-S23.
9. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-
Rosett J, Sowers MR: The obese without cardiometabolic risk factor
clustering and the normal weight with cardiometabolic risk factor
clustering: prevalence and correlates of 2 phenotypes among the US
population (NHANES 1999-2004). Arch Intern Med 2008, 168:1617-1624.
10. Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D: Reproducibility and
relative validity of the short questionnaire to assess health-enhancing
physical activity. J Clin Epidemiol 2003, 56:1163-1169.
11. Kemper HGC, Ooijendijk WTM, Stiggelbout M: Consensus over de
Nederlandse Norm voor Gezond Bewegen. Tijdschrift voor Sociale
Gezondheidszorg 2000, 78:180-183.
12. Stalman WA, Scheltens T, Burgers JS, Hukkelhoven CW, Smorenburg SM,
Banga JD, Dippel DW: NHG-Standaard Cardiovasculair risicomanagement
Houten: Bohn Stafleu van Loghum; 2006.
13. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,
Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic
syndrome: a joint interim statement of the International Diabetes
Federation Task Force on Epidemiology and Prevention; National Heart,
Lung, and Blood Institute; American Heart Association; World Heart
Federation; International Atherosclerosis Society; and International
Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
14. Taubert K, Tracy RP, Vinicor F, Pearson TA, Mensah GA, Alexander RW,
Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y,
Myers GL, Rifai N, Smith SC Jr: Markers of inflammation and
cardiovascular disease: application to clinical and public health practice:
A statement for healthcare professionals from the Centers for Disease
Control and Prevention and the American Heart Association. Circulation
2003, 107:499-511.
15. Morley JJ, Kushner I: Serum C-reactive protein levels in disease. Ann N Y
Acad Sci 1982, 389:406-418.
16. Macy EM, Hayes TE, Tracy RP: Variability in the measurement of C-reactive
protein in healthy subjects: implications for reference intervals and
epidemiological applications. Clin Chem 1997, 43:52-58.
17. Dupuy AM, Jaussent I, Lacroux A, Durant R, Cristol JP, Delcourt C: Waist
circumference adds to the variance in plasma C-reactive protein levels
in elderly patients with metabolic syndrome. Gerontology 2007,
53:329-339.
18. Santos AC, Lopes C, Guimaraes JT, Barros H: Central obesity as a major
determinant of increased high-sensitivity C-reactive protein in metabolic
syndrome. Int J Obes (Lond) 2005, 29:1452-1456.
19. Zuliani G, Volpato S, Galvani M, Ble A, Bandinelli S, Corsi AM, Lauretani F,
Maggio M, Guralnik JM, Fellin R, Ferrucci L: Elevated C-reactive protein
levels and metabolic syndrome in the elderly: The role of central obesity
data from the InChianti study. Atherosclerosis 2009, 203:626-632.
20. Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-
Urdaneta C, Lee D, Goldberg R: C-reactive protein is elevated in obese
patients with the metabolic syndrome. Diabetes Res Clin Pract 2006,
71:92-100.
21. Gonzalez AS, Guerrero DB, Soto MB, Diaz SP, Martinez-Olmos M, Vidal O:
Metabolic syndrome, insulin resistance and the inflammation markers C-
reactive protein and ferritin. Eur J Clin Nutr 2006, 60:802-809.
22. Kressel G, Trunz B, Bub A, Hulsmann O, Wolters M, Lichtinghagen R,
Stichtenoth DO, Hahn A: Systemic and vascular markers of inflammation
in relation to metabolic syndrome and insulin resistance in adults with
elevated atherosclerosis risk. Atherosclerosis 2009, 202:263-271.
23. Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, Kang JH, Kim SW,
Lee MH, Park JR: C-reactive protein concentrations are related to insulin
resistance and metabolic syndrome as defined by the ATP III report. Int J
Cardiol 2004, 97:101-106.
24. Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, Abe M,
Katoh T, Ohtsuka N: High-sensitivity C-reactive protein and gamma-
glutamyl transferase levels are synergistically associated with metabolic
syndrome in community-dwelling persons. Cardiovasc Diabetol 2010, 9:87.
25. Mahajan A, Jaiswal A, Tabassum R, Podder A, Ghosh S, Madhu SV,
Mathur SK, Tandon N, Bharadwaj D: Elevated levels of C-reactive protein
as a risk factor for Metabolic Syndrome in Indians. Atherosclerosis 2012,
220:275-281.
26. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O,
Brook GJ, Levy Y: Obesity is the major determinant of elevated C-reactive
protein in subjects with the metabolic syndrome. Int J Obes Relat Metab
Disord 2004, 28:674-679.
27. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R,
Brenner H, Koenig W: Association between C-reactive protein and
features of the metabolic syndrome: a population-based study. Diabetes
Care 2000, 23:1835-1839.
28. Lu B, Yang Y, Yang Z, Feng X, Wang X, Zhang Z, Hu R: Insulin resistance in
Chinese patients with type 2 diabetes is associated with C-reactive
protein independent of abdominal obesity. Cardiovasc Diabetol 2010, 9:92.
29. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M,
Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N,
Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of C-reactive
protein with adiponectin in blood stream and adipose tissue. Circulation
2003, 107:671-674.
30. Bouchard L, Tchernof A, Deshaies Y, Marceau S, Lescelleur O, Biron S,
Vohl MC: ZFP36: a promising candidate gene for obesity-related
metabolic complications identified by converging genomics. Obes Surg
2007, 17:372-382.
31. Faucher G, Guenard F, Bouchard L, Garneau V, Turcot V, Houde A,
Tchernof A, Bergeron J, Deshaies Y, Hould FS, Lebel S, Marceau P, Vohl MC:
Genetic contribution to C-reactive protein levels in severe obesity. Mol
Genet Metab 2011.
32. Niehoff AG, van Haeften TW, Onland-Moret NC, Elbers CC, Wijmenga C, van
der Schouw YT: C-reactive protein is independently associated with
den Engelsen et al. Cardiovascular Diabetology 2012, 11:25
http://www.cardiab.com/content/11/1/25
Page 6 of 7glucose but not with insulin resistance in healthy men. Diabetes Care
2007, 30:1627-1629.
33. Janssen PG, Gorter KJ, Stolk RP, Rutten GE: Low yield of population-based
screening for Type 2 diabetes in the Netherlands: the ADDITION
Netherlands study. Fam Pract 2007, 24:555-561.
doi:10.1186/1475-2840-11-25
Cite this article as: den Engelsen et al.: High-sensitivity C-reactive
protein to detect metabolic syndrome in a centrally obese population:
a cross-sectional analysis. Cardiovascular Diabetology 2012 11:25.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
den Engelsen et al. Cardiovascular Diabetology 2012, 11:25
http://www.cardiab.com/content/11/1/25
Page 7 of 7